Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Novel α-aminophosphonate derivates synthesis, theoretical calculation, Molecular docking, and in silico prediction of potential inhibition of SARS-CoV-2

Rachida kerkoura,b,c, Nadjib Chafai d, Ouahiba Moumenia, Saleh Chafaa

a Laboratory of Electrochemistry of Molecular Materials and Complex (LEMCC), Department of Process Engineering, Faculty of Technology, University of Ferhat Abbas Setif-1, El Maabouda 19000 Setif, Algeria
b Department of Science and Technology, Institute of Science and Technology, University of Abdelhafidh Boussouf, Mila, Algeria

d Contents lists available at ScienceDirect
Journal of Molecular Structure
journal homepage: www.elsevier.com/locate/molstr

A R T I C L E   I N F O

Article history:
Received 24 March 2022
Revised 7 September 2022
Accepted 21 September 2022
Available online 28 September 2022

Keywords:
Mpro
RdRp
SARS-CoV-2
Synthesis
α-aminophosphonate
DFT
Molecular docking

A B S T R A C T

Using the Density Functional Theory approach and in silico docking, the current study analyzes the inhibitory role of a novel α-aminophosphonate derivative against SARS-CoV-2 major protease (Mpro) and RNA dependent RNA polymerase (RdRp) of SARS-CoV-2. FT-IR, UV–Vis, and NMR (1H, 13C, 31P) approaches were used to produce and confirm the novel α-aminophosphonate derivative. The quantum chemical parameters were determined, and the reactivity of the synthesized molecule was discussed using DFT at the B3LYP/6-31G(d,p) level. In addition, the inhibitory function of the investigated derivative for SARS-CoV-2 major protease (Mpro) and RNA dependent RNA polymerase (RdRp) was estimated using in silico docking. These discoveries could pave the way for novel SARS-CoV-2 therapies to develop and be tested.

© 2022 Elsevier B.V. All rights reserved.

1. Introduction

Coronaviridae virus SARS-CoV-2. This infectious disease first surfaced in the Chinese city of Wuhan in December 2019, soon spreading throughout China and then internationally, resulting in a global outbreak. In China, on November 9th [1], the COVID-19 virus had spread to over 190 countries, causing 50 million illnesses and 1 250 000 deaths [2]. Covid-19 is a respiratory illness that can be deadly in elderly or chronically ill patients. It is spread by intimate contact with sick individuals. Many doctors have been waiting for the SARS-CoV-2 coronavirus to emerge. When confronted with an unknown illness, they often had to do what they had on hand to treat their patients; this pushed them to experiment with illegal medications and therapies. Covid-19 stands for “Coronavirus Illness 2019,” a disease caused by the even though a health crisis caused the COVID-19 pandemic, it infected millions of people worldwide and caused unprecedented tension and a surge in all aspects of life. COVID-19 has caused widespread misery and human suffering. It has hurt social life, health care systems, educational systems, technological, industrial, agricultural production, and financial systems worldwide, pushing people’s socioeconomic wellbeing to the brink of collapse [3]. However, because of the pandemic’s global nature, people from all over the world may band together and work together to slow and stop the spread of the disease and find new drug treatments.

In this context, and according to a study published in the journal Infectious Diseases and Therapy by the University of Pennsylvania (United States), 115 different drugs and remedies were prescribed to the first patients with Covid-19, a total of 9152 patients, and the vast majority of these treatments were administered outside of standard care protocols and without proven effectiveness, with only a small number of articles published with exploitable data on their efficacy [4]. Antivirals, particularly the Lopinavir/ritonavir combination, are among these medications, as are antibiotics and corticosteroids such as methylprednisolone. Patients have also been treated with antibodies, while others have been treated solely or with traditional medical remedies such as herbal decoctions [5]. In Algeria, for example, two medications, Hydroxychloroquine (HCQ) and Chloroquine(CQ) have been approved for the treatment of individuals with coronavirus illness 2019 (COVID-19) [6], against COVID-19 [7–11]. Also, some researchers are evaluating drugs approved for other vision conditions to see

https://doi.org/10.1016/j.molstruc.2022.134196
0022-2860/© 2022 Elsevier B.V. All rights reserved.
if they can be repositioned for treatment and prevention in animals and humans [12–14], and regulators have yet to approve any drugs for the treatment of SARS-CoV-2 infection. Researchers need to understand better the dynamics of SARS-CoV-2, the virus that causes the disease. However, due to the difficulty of experimental measurements and the rapid progression of the coronavirus, they have turned to models to better understand how the disease develops in the body, particularly in the blood and immune system [15–17], in order to model drug treatments and identify ideal delivery methods [18–20].

As a result, various research teams worldwide have already conducted an extensive study to assess the efficacy of several medications α-aminophosphonates, structural counterparts of the corresponding α-amino acids, have gotten much attention in this context, and their synthesis has gotten much attention in synthetic organic chemistry and medicinal chemistry [21]. They play an important role and exhibit various biological and biochemical properties. They effectively inhibit the growth of plasmidium falciparum, the parasite that causes malaria, in test tubes [22]. They also act as inhibitors of specific enzymes, such as HIV protease, thrombin, and human collagenase, and suppress the growth of various tumours and viruses [23,24]. Antibiotics [25], antimicrobials [26], anticancer agents [27], and antioxidants agents [28] are all examples of α-aminophosphonates. For coronaviruses, such as SARS-CoV-2 [29–33], enzymes such as Mpro/3CLpro and RdRp, which play significant roles in viral transcription and replication, have been regarded as interesting therapeutic targets. CoV-2 is difficult, this study sought to establish a link between some quantum descriptors and the inhibitory action of the examined α-aminophosphonates for SARS-CoV-2. The Density Functional Theory (DFT) approach derived quantum chemical parameters at the B3LYP/6-31G(d,p) level. The energy of the highest occupied molecular orbital (EHOMO), the energy of the lowest unoccupied molecular orbital (ELUMO), the energy gap (ΔEgap), global hardness (η), global softness (σ), absolute electronegativity (χ), and the electrophilicity index (ω) are some of the characteristics. This study was also used to predict the inhibitory activity of the examined α-aminophosphonate for SARS-CoV-2 in silico docking.

2. Materials and methods

2.1. Experimental

All of the chemical substances used in this research were acquired from Sigma-Aldrich and used without additional purification. The melting point of the obtained compound was determined using an open capillary method in Buchi Melting Point B-540 (60 - 900 °C). In contrast, UV–vis spectra were obtained using a JASCO V-650 UV–Vis spectrophotometer with quartz cells of 1 cm path length in Methanol between 200 and 800 nm. FT-IR spectra were obtained using a JASCO 4200 spectrometer between 4000 and 200 cm 1. Finally, the 1H, 13C, and 31P NMR spectra were obtained using a Bruker AV III 300 MHz in DMSO–d6 with tetramethylsilane (TMS) as an internal reference.

In a Kabachnik-Fields reaction [34], an equimolar amount of 4-amino pyridine (1 mmol, 0.094 mg), 4-hydroxybenzaldehyde (1 mmol, 1.22 mg), and triethyl phosphate (1 mmol, 1.66 mg) were combined to make diethyl(4-hydroxyphenyl) [[(pyridine-4-yl)amino]methyl]phosphonate. The reaction was monitored by chromatography TLC (n-hexane/ethanol acetate) on Merck pre-coated GP254 silica plates. After that, the solid product was recrystallized in ethanol and dried at room temperature. The structure of the obtained α-aminophosphonate was confirmed by FT-IR, UV–Vis, 1H, 13C, and 31P NMR spectra (DH-PAMP).

2.2. Computational details

2.2.1. Quantum chemical calculations

The Lee-Yang-Parr nonlocal correlation functional (RB3LYP) and Beck’s three-parameter exchange functional (B3LYP) with the 6-31G (d, p) basis set were used in all calculations [35,36]. The Gaussian 09 program parcel [37] was used to complete the investigated structure’s full optimization and vibrational study. Gauss View 5.0.8 computer program was used to visualize the results [38]. TD-SF was used to forecast UV–Vis spectra using the B3LYP/6-31G 31P (d,p) level, while 1H and 13C chemical shift calculations were performed using the 6.31G(dp) basis set in DMSO solution. The isotropic chemical shifts concerning tetramethylsilane were calculated using the isotropic shielding values (TMS). The dipole moment (μ), energy gap (ΔEgap), chemical hardness (η), chemical softness (σ), electronegativity (χ), and global electrophilicity index (ω) were estimated with the following formula [39–41].

\[
\Delta E_{\text{gap}} = E_{\text{LUMO}} - E_{\text{HOMO}}
\]

(1)

\[
\eta = \frac{E_{\text{LUMO}} - E_{\text{HOMO}}}{2}
\]

(2)

\[
\sigma = \frac{1}{\eta}
\]

(3)

\[
\chi = -\frac{(E_{\text{HOMO}} + E_{\text{LUMO}})}{2}
\]

(4)

\[
\omega = \left(\frac{\chi^2}{2\eta}\right)
\]

(5)

2.2.2. Molecular docking

One of the most basic and essential strategies for drug development is molecular docking analysis [42–44]. It was carried out to determine the ligand’s binding affinity for SARS-CoV-2 major protease (Mpro, also known as 3CLpro or chymotrypsin-like protease) and RNA dependent RNA polymerase (RdRsp) [45]. Mpro and PLpro are proteases with the codes 6LU7 and 7BV2 [46] in the Protein Data Bank (PDB). Autodock software version 4.2.6 [47] was used to visualize the molecular docking process, including a built-in grid of 30 × 30 × 30 Å3. The DH-PAMP-RdRp and DH-PAMP-RdRp complex were visualized and depicted using Accelrys Discovery Studio [48].

3. Results and discussion

3.1. Experimental

3.1.1. IR spectra

DH-PAMP stands for Diethyl[(4-hydroxyphenyl) [[(pyridine-4-yl)] amino]methyl]phosphonate. Mol.Wt: 336. 322, Yield: 85% white solid, mp 90 °C. The vibrational analysis is an effective approach to locating vibrational modes linked with a compound’s projected specific molecular structure. A non-linear molecule with N atoms has many potentially active observable fundamentals of three translational and three rotational degrees of freedom (3N-6). The vibrational bands of DH-PAMP were allocated using the GaussView molecular visualization tool [38]. There are 126 common vibration modes for the DH-PAMP molecule because it comprises 44 atoms. Fig. 2 shows the measured FT-IR spectra of DH-PAMP beside the hypothesized infrared spectra. Table 1 summarizes the observed and estimated frequencies using DFT/B3LYP with the 6-31G (d, p) basis set and associated DH-PAMP probable assignments. The functional group’s unique peaks may be seen in the IR spectra of the α-aminophosphonate molecule: Positive evidence for the synthesis
of functional groups is the elimination of the aldehyde's distinctive carbonyl peaks and the imprinting of the primary amine group on the produced molecule. \( \nu_{\text{N-H}} \) (3253), \( \nu_{\text{C-H (aliphatic)}} \) (2844–2999), \( \nu_{\text{C} = \text{C}} \), \( \nu_{\text{C} = \text{N}} \) aromatiques (1650–1543), \( \nu_{\text{P-CH}_2} \) (1381), \( \nu_{\text{P-O}} \) (1215), \( \nu_{\text{C}} \) aromatiques (1039), \( \nu_{\text{C}} \) aliphatiques (959), \( \nu_{\text{P-O}} \) (764), \( \nu_{\text{P-O-C}} \) (697). There is a good match between the experimental and computed frequencies (Fig. 2).

### 3.1.2. UV-vis analysis

Fig. 3 shows the measured UV-vis spectra of DHPAMP and the hypothesized infrared spectra. They were carried out in methanol. The spectra of the synthesized product differ significantly from those of the starting products, with considerable displacements of the bands' maximum values and the emergence of the shoulders typical of \( \alpha \)-aminophosphonate. DHPAMP's UV-Vis spectra are characterized by three absorption bands positioned at: A high-octane band based on \( \lambda_{\text{max}} = 206 \) characterizes the molecule. In contrast, another band at \( \lambda_{\text{max}} = 243 \) nm corresponds to the \( \text{C} = \text{C} \) group of the aromatic ring’s \( \pi \rightarrow \pi^* \) transitions. The

### 3.1.3. NMR spectroscopy

NMR spectroscopies of 1H, 13C, and 31P were also used to describe the molecule. The title compound’s 1H, 13C, and 31P NMR spectra were recorded using TMS as an internal standard and DMSO as the solvent, following the numbering scheme indicated in (Supplementary file). The DFT (B3LYP) approach with the 6-31G (d, p) basis sets was used to produce GIAO 1H and 13C chemical shift values (concerning TMS), which were compared to experimental 1H and 13C chemical shift values. Table 2 summarizes the general conclusions of this calculation, along with experimental values. In addition, we present correlation graphs based on calculations in Fig. 4 to compare with experimental observations. As shown in Table 2 and Fig. 5 the experimental values are in good agreement with the DFT/B3LYP/6-31G (d,p) results.

| Experimental IR (cm\(^{-1}\)) | Calculated \( \text{cm}^{-1} \) B3LYP/6-31G(d, p) | Assignment |
|-----------------------------|---------------------------------|------------|
| 3253 | 3526 | \( \nu_{\text{N-H}} \) |
| 2844–2999 | 3225–3039 | \( \nu_{\text{C-H (aliphatic)}} \) |
| 1650–1543 | 1561–1659 | \( \nu_{\text{C}} \) aromatiques, \( \nu_{\text{C}} \) \( \text{C} = \text{N} \) /aromatiques |
| 1381 | 1309 | \( \nu_{\text{C} = \text{C}} \) |
| 1215 | 1211 | \( \nu_{\text{P-CH}_2} \) |
| 1039 | 959 | \( \nu_{\text{C}} \) aliphatiques |
| 764 | 768 | \( \nu_{\text{P-O}} \) |
| 697 | 744 | \( \nu_{\text{P-O-C}} \) |

n→\( \pi^* \) transitions associated with the presence of heteroatoms (O, N, and P) on the molecular structure of the examined molecule are allocated to the band that appeared \( \lambda_{\text{max}} = 293 \) nm, while \( \lambda_{\text{max}} = 198 \) nm, \( \lambda_{\text{max}} = 232 \) nm, \( \lambda_{\text{max}} = 309 \) nm are the calculated values by the (B3LYP/6-31G(d, p) technique, respectively. These findings show distinct discrepancies between the spectra of the acquired product and the spectra of the starting products, with good agreement between experimental and predicted values for the current molecule (Supplementary file).
Table 2
Isotropic chemical shifts (ppm) for the title molecule, both experimental and theoretical (13C and 1H).

| Atom       | Experimental | B3LYP/6-31G(d,p) |
|------------|--------------|-----------------|
| 1-C        | 128.84       | 127.29          |
| 2-C        | 129.14       | 128.20          |
| 3-C        | 132.51       | 135.67          |
| 4-C        | 129.20       | 133.14          |
| 5-C        | 128.89       | 128.00          |
| 6-C        | 191.30       | 159.87          |
| 11-C       | 62.17        | 67.24           |
| 12-C       | 163.91       | 157.64          |
| 14-C       | 115.11       | 126.54          |
| 15-C       | 116.34       | 126.79          |
| 16-C       | 157.39       | 153.11          |
| 18-C       | 140.22       | 152.19          |
| 28-C       | 68.91        | 70.68           |
| 32-C       | 16.68        | 25.38           |
| 37-C       | 70.26        | 75.35           |
| 41-C       | 16.79        | 27.34           |
| 7-H        | 6.75         | 8.16            |
| 8-H        | 7.75         | 6.17            |
| 9-H        | 7.77         | 7.17            |
| 10-H       | 6.98         | 6.16            |
| 12-H       | 4.80         | 3.87            |
| 17-H       | 7.24         | 8.17            |
| 19-H       | 7.35         | 8.17            |
| 20-H       | 8.08         | 9.42            |
| 21-H       | 8.10         | 9.51            |
| 23-H       | 4.83         | 4.05            |
| 26-H       | 9.80         | 9.93            |
| 29-H       | 3.84         | 5.06            |
| 33-H       | 1.13         | 1.97            |
| 34-H       | 1.13         | 1.64            |
| 35-H       | 1.13         | 0.94            |
| 36-H       | 3.84         | 5.06            |
| 38-H       | 3.99         | 5.36            |
| 39-H       | 3.99         | 5.38            |
| 42-H       | 1.13         | 2.05            |
| 43-H       | 1.13         | 2.72            |
| 43-H       | 1.13         | 3.00            |

Table 3
Quantum chemical parameters of DHPAMP calculated using DFT.

| Quantum chemical parameters | Values |
|-----------------------------|--------|
| Total energy E_{tot} (eV)   | -37.393.7436 |
| E_{HOMO} (eV)               | -5.89970 |
| E_{LUMO} (eV)               | -0.26122 |
| ΔE_{gap}(E_{LUMO}-E_{HOMO}) | 5.63348 |
| Dipole moment (μ) (debye)   | -4.8495 |
| Hardness (η)                | 2.81924 |
| Softness (σ)                | 0.45612 |
| Electronegativity (χ)       | 3.08046 |
| Electrophilicity (ω)        | 1.68294 |

3.2. Computational achievements

3.2.1. DFT calculations

Fig. 5 depicts the optimized structure and atom numbering of the examined molecule achieved using the B3LYP/6-31G technique. The calculated total energy (E_{tot}), the dipole moment (μ), energy gap (ΔE_{gap}), chemical hardness (η), chemical softness (σ), electronegativity (χ), and global electrophilicity index (ω) are all shown in Table 3.

Frontier Molecular Orbitals (FMO) refers to two molecular orbital frontiers known as HOMO (Highest Occupied Molecular Orbital) and LUMO (Lowest Unoccupied Molecular Orbital), or LUMO is directly related to electron affinity. In contrast, HOMO is directly related to ionization potential [48,49]. These orbitals aid in understanding the molecule’s chemical stability and reactivity [50,51]. Furthermore, the estimated value of ΔE_{gap} shows the energy required to excite a molecule’s electrons. If the HOMO-LUMO energy gap is small, molecules can be unstable and readily excited, whereas if the ΔE_{gap} is big, molecules can be very stable and chemically reactive [52]. The B3LYP/6-31G (d, p) approach was used to calculate the FMOs in electronic transitions and their energies and their orbital energy gap (ΔE_{gap}) to predict the energy characteristics and reactivity of the generated compound against the COVID-19 virus. E_{HOMO} and LUMO have -5.89970 eV and -0.26122 eV, respectively, and the energy separation between the HOMO and the LUMO has a value of 5.63348 eV for the most stable conformer.

The polarity of pharmacological molecules is denoted by the dipole moment (μ), which is a three-dimensional vector and is connected with the fractional electric charge distribution in these compounds [53]. As a result, its significance is demonstrated in reaction mechanisms and relates to molecules’ ability to interact with other molecular species. For example, the dipole moment for the molecule DHPAMP is 4.3301 Debye, which indicates that it has a high ability to interact with the environment.

Furthermore, the hardness(η) and local softness (σ) of drug molecules can be used to assess their resistance to deformation of their electron clouds or polarization [54]. The examined compound’s hardness and local softness were computed and determined to be 2.81924 and 0.45612 eV, respectively. Electronegativity (χ) is a metric that compares an atom’s attraction to bonding electrons in molecules to that of other atoms. The molecule’s electronegativity is calculated and found to be 3.08046 eV, showing that the ligand is an electronegative species. The electronegativity index(ω) is used to describe a molecule’s biological activity [55], with higher values indicating stronger electrophilicity and lower values indicating a weak electrophile [56]. We can divide organic molecules into three categories based on their electrophilicity values: marginal electrophiles with a value of less than 0.8 eV, moder-
ate electrophiles between 0.8 and 1.5 eV, and strong electrophiles with a value greater than 1.5 eV [57]. The value of 1.68294 eV for the researched ligand indicates that it is a good electrophile capable of receiving an electron doublet to form bonds with another reagent, which must be a nucleophile.

Because atomic charges affect dipole moment, molecular polarizability, electronic structure, and many other aspects of molecular systems, while Mulliken atomic charge calculation is a crucial parameter for molecular systems, medicinal compounds’ atomic Mulliken charges can be utilized to prove their adsorptive locations [58]. The Mulliken atomic charges of the estimated compound were calculated using DFT with B3LYP 6-311G (d,p) as a basis set and are listed in Table 4 and are plotted in Fig. 6. According to the data, the oxygen and nitrogen atoms have the most significant negative charges because of molecular relaxation. However, the hydrogen atoms also cover the positive charges. The majority of negative charges are concentrated on the atoms N22, N24, O25, O30, O31 and O40, which are thought to be the active region of adsorption [59]. Furthermore, most of the positive charges are carried by the P27 atom.

3.2.2. Structure and preparation of MPro for docking studies

Because of its role in processing translated polyproteins, Mpro was chosen as a docking study target. In contrast, RdRp was chosen because of its significance in viral genome replication and transcription. The DHPAMP ligand was docked with receptors to de-
Table 4

| Symbol | MM Charge | Symbol | MM Charge |
|--------|-----------|--------|-----------|
| 1C     | −0.10     | 23H    | 0.27      |
| 2C     | −0.11     | 24N    | −0.45     |
| 3C     | 0.14      | 25O    | −0.55     |
| 4C     | −0.12     | 26H    | 0.31      |
| 5C     | −0.13     | 27P    | 1.17      |
| 6C     | 0.32      | 28C    | 0.04      |
| 7H     | 0.10      | 29H    | 0.12      |
| 8H     | 0.09      | 300    | −0.54     |
| 9H     | 0.08      | 310    | −0.60     |
| 10H    | 0.07      | 32C    | −0.33     |
| 11C    | −0.21     | 33H    | 0.11      |
| 12H    | 0.14      | 34H    | 0.11      |
| 13C    | 0.36      | 35H    | 0.12      |
| 14C    | −0.14     | 36H    | 0.13      |
| 15C    | −0.12     | 37C    | 0.04      |
| 16C    | 0.08      | 38H    | 0.11      |
| 17H    | 0.07      | 39H    | 0.11      |
| 18C    | 0.08      | 40O    | −0.53     |
| 19H    | 0.07      | 41C    | −0.33     |
| 20H    | 0.09      | 42H    | 0.10      |
| 21H    | 0.09      | 43H    | 0.12      |
| 22N    | −0.61     | 44H    | 0.15      |

Fig. 6. Mulliken charges charge distribution of DHPAMP compound.

determine the correct conformation of DHPAMP in the receptor and the secondary forces that result from the ligand and the receptor’s active amino acids. The molecular docking of the DHPAMP ligand with the Mpro and RdRp receptors was used to determine the proper conformation of the ligand in the receptor and the secondary forces that occur from DHPAMP binding to the receptor’s active amino acids. As a result, novel medication designs are developed. The non-covalent bonds, π-π* and π-σ interactions between the active amino acids of the Mpro and RdRp target receptors and the DHPAMP ligand were assessed based on the minimal binding energy. Fig. 7 depict Mpro and RdRp crystal structures, respectively, while Fig. 8 depicts the crystal structures of the best docked Mpro-DHPAMP and RdRp-DHPAMP complexes. The ligand binds to RdRp stronger than to the Main Protease, and it prefers to bind in the outer structure of Mpro, whereas it prefers to bind in the inner pocket of RdRp, as seen in Fig. 8. According to the docking studies, the ligand showed great potential for binding to the active site of COVID-19 Mpro, and RdRp could be promising therapeutic agents in COVID-19 infections.

With binding affinities of −6.40 kcal/mol and −8.40, respectively, the docking of DHPAMP with SARS-CoV-2 Mpro and RdRp demonstrated significant interactions in the central pocket. For Mpro, DHPAMP created van der Waals forces with the amino acids HIS41, MET49, HIS164, MET165, GLU166 and GLN189, as well as hydrogen bonds with the amino acids SER144, HIS163, and GLU166 (Fig. 9a). While for RdRp, it created van der Waals forces with LYS272, TYR273, ASP274, PHE275, and GLU277 and hydrogen bonds with LEU271, LYS272, ASP274, THR276 and GLU277 (Fig. 9b). The lowest binding energy in molecular interactions is shown by comparing the estimated binding energies of DHPAMP and other medicines (Table 5). lowest bending energy in interactions with Mpro and RdRp, suggesting that it has a higher affinity for binding and that the complexes produced by Mpro-DHPAMP and RdRp-DHPAMP are more stable than those produced by the other compounds.

Fig. 7. Crystal structures of Mpro and RdRp.

Fig. 8. Best docked model visualization with Mpro-DHPAMP and RdRp-DHPAMP complexes.
Fig. 9. 2D, 3D Binding-interaction diagrams of DHPAMP with SARS-CoV-2 main protease (a) and RNA dependent RNA polymerase (b).

Table 5
Molecular docking results of DHPAMP and some drugs with Mpro and RdRp.

| Compounds               | Mpro Docking score (Kcal/mol) | RdRp Docking score (Kcal/mol) |
|-------------------------|-------------------------------|-------------------------------|
| This work (DHPAMP)      | −6.40                         | −8.40                         |
| HDZPA [20]              | −6.00                         | −7.70                         |
| Chloroquine [60]        | −4.9                          | −5.4                          |
| Hydroxychloroquine [61] | −5.5                          | −5.6                          |
| Remdesivir [62,63]      | −4.96                         | −7.60                         |

4. Conclusion

A novel α-aminophosphonate derivative was produced and characterized using one-pot three-component processes. The obtained chemical is a stable solid with high melting temperature, and its structure was identified using the IR, UV–Vis, 1H, 13C, and 31P NMR spectra. DFT method and molecular docking calculations were used to study derivative of α-aminophosphonate. Quantum chemical computations (DFT) B3LYP/6-31G (d, p) were used to optimize the molecular structures of this derivative, and their geometrical parameters were identified. Additionally, molecular docking research was carried out to evaluate the synthesized ligand’s affinity for binding to the main protease (Mpro) of the SARS-CoV-2 and the RNA dependent RNA polymerase (RdRp). The obtained $E_{\text{HOMO}}$, $E_{\text{LUMO}}$, and $\Delta$Egap values show that the ligand is a reactive and unstable species. The predicted MEP maps show potential nucleophilic and electrophilic attack sites, and the Mulliken charges show that there may be active interaction sites as well. The investigated ligand’s interactions with Mpro and RdRp showed that it can bind to several bonding contacts. The derivative can be effective in treating this condition since, according to the synthesis, computational analysis, and in silico docking data, it is a potent COVID-19 viral inhibitor.
Authors’ contributions
Rachida Kerkour (Doctor): Writing, review and editing, Conceptualization, Resources and Investigation, Theoretical studies and Review.
Nadjib Chafai (Doctor): Resources and Investigation, Theoretical studies.
Ouahla Moumeni (Doctor): Supervision.
Salah Chafaa (Professor): Project management, Funding acquisition.

Declaration of Competing Interest
The authors declare no conflict of interest.

Data availability
Data will be made available on request.

Certificate of Originality
The work reported in the paper (Novel α-aminophosphonate derivatives synthesis, theoretical calculation, Molecular docking, and in silico prediction of potential inhibition of SARS-CoV-2) submitted for publication in journal of molecular structure is original and has not been submitted for publication elsewhere.

All authors have seen and approved this manuscript and consent to having their name in the list of authors, thereby taking responsibility for the results contained in the manuscript.

Proper citations to the previously reported works have been given.

Funding
This research was supported by the General Directorate for Scientific Research and Technological Development (DGRSDT), Algerian Ministry of Scientific Research, Laboratory of Electrochemistry of Molecular Materials and Complex (LEMMC), Ferhat ABBAS University of Sétif.

Availability of data and material
Not applicable.

Code availability
Not applicable.

Acknowledgements
This research was supported by Algerian Ministry of Scientific Research, Laboratory of Electrochemistry of Molecular Materials and Complex (LEMMC), Ferhat ABBAS University of Sétif.

Supplementary materials
Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.molstruc.2022.134196.

References
[1] X. Yang, Y. Yu, J. Xu, H. Shu, H. Liu, Y. Yu, Y. Shang, Clinical course and outcomes of critically ill patients with SARS-COV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study, Lancet Respir. Med. 8 (5) (2020) 475–481.
[2] J.K. Jackson, Global economic effects of COVID-19, Congression. Res. Serv. (2021).
[3] O.M. Ozkendir, M. Askar, N.E. Kocer, Influence of the epidemic COVID-19: an outlook on health, Business and Scientific Studies, Lab-in-Silico 1 (1) (2020) 26–30, doi:10.22034/tablisilico2001026.
[4] K. Thorlund, L. Dros, J. Park, G. Hsu, J.L. Forrest, E.J. Mills, A real-time dashboard of clinical trials for COVID-19, The Lancet Digit. Health 2 (6) (2020) e286–e287.
[5] W. Tai, L. He, X. Zhang, J. Pu, D. Voronin, S. Jiang, L. Du, Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine, Cell. Mol. Immunol. 17 (6) (2020) 613–620.
[6] M. Wang, R. Cao, L. Zhang, X. Yang, J. Liu, M. Xu, G. Xiao, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res. 30 (3) (2020) 269–271.
[7] E. de Wit, F. Feldmann, J. Cronin, R. Oumou, A. Okumura, T. Thomas, H. Feldmann, Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection, Proc. Natl. Acad. Sci. 117 (12) (2020) 6771–6776.
[8] M.H. Bakhari, K. Mahmood, S.A. Zahra, Over view for the trend of COVID-19 pandemic: a guide for the Pathologists, Health care workers and community, Pak. J. Med. Sci. 36 (2020) 531 COVID19-54.
[9] P. Colson, J.M. Rolain, D. Raoult, Chloroquine for the 2019 novel coronavirus SARS-CoV-2, Int. J. Antimicrob. Agents 55 (3) (2020) 105923.
[10] P. Gautret, J.C. Lagier, P. Parola, L. Meddeb, M. Mailhe, B. Doudier, D. Raoult, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int. J. Antimicrob. Agents 56 (1) (2020) 105949.
[11] M.S. Khurroo, Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19): Facts, fiction and the hype: a critical appraisal, Int. J. Antimicrob. Agents 56 (3) (2020) 106101.
[12] S.J. Park, K.M. Yu, Y.S. Kim, S.M. Kim, E.H. Kim, S.G. Kim, Y.K. Choi, Antiviral efficacies of FDA-approved drugs against SARS-CoV-2 infection in ferrets, Mbio 11 (3) (2020) e01114-e01120.
[13] J. Gao, Z. Tian, X. Yang, Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical trials, Biosci. Trends (2020).
[14] Liu, C., Zhou, Q., Li, Y., Garner, L.V., Watkins, S.P., Carter, L.J., Albaugh, D., 2020. Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases.
[15] H. Qi, Z. Hu, Z. Yang, J. Zhu, J.J. Wu, C. Cheng, L. Zheng, Capacitive aptasensor coupled with microfluidic enrichment for real-time detection of trace SARS-CoV-2 nucleocapsid protein, Analytical chemistry. in order to model drug treatments and identify ideal delivery methods (2022).
[16] T.Y. Zha, O. Castillo, H. Jahanshahi, A. Yusuf, M.O. Alasassi, F.E. Alsaadi, Y.M. Chu, A fuzzy-based strategy to suppress the novel coronavirus (2019-N-CoV) massive outbreak, Appl. Comput. Math. (2021) 160–176.
[17] A. Swargiary, N. Wary, T. Das, M.K. Roy, H. Boro, Covid-19 and Fungal Co-Infection: A Literature Review with Special Reference to India, Adv. J. Sci. Eng. 3 (1) (2022) 72–80, doi:10.22034/advance202013072.
[18] H. Behzadi, P. Roonasi, D. van der Spoe, S. Manzetti, Relationship between electronic properties and drug activity of seven quinoxaline compounds: a DFT study, J. Mol. Struct. 1091 (2015) 196–202.
[19] N. CHAFAI, K. Benbougouerra, S. Chafaa, Quantum chemical study of Hydroxychloroquine and Chloroquine drugs used as a treatment of COVID-19, Iran. J. Chem. Chem. Eng. (2020).
[20] K. Benbougouerra, N. Chafai, S. Chafaa, Y.I. Touahria, H. Tlidjane, New α-hydrazinophosphonic acid: synthesis, characterization, DFT study and in silico prediction of its potential inhibition of SARS-CoV-2 main protease, J. Mol. Struct. 1239 (2021) 130480.
[21] P. Kafarski, R. Lejczak, Aminophosphonic and aminophosphinic acids. chemistry and biological activity, in: V.P. Kukhar, HR Hudson (Eds.), Synthesis of Phospho-And Phosphonopptides, 2000, pp. 173–205.
[22] F. Palacios, M.I. Gil, E.M. de Marigorta, M. Rodriguez, Synthesis of 3-phosphorylated 2-aza-1,3-dienes from nitrones derived from bisphosphonates, Tetrahe- dron Lett. 40 (12) (1999) 2411–2414.
[23] J. Oleksyszyn, J.C. Powers, Irreversible inhibition of serine proteases by peptide derivatives of L-alpha-aminoalkyl-phosphonic diethyl esters, Biochemistry 30 (2) (1991) 485–493.
[24] D. Green, G. Patel, S. Elgindy, J.A. Baban, G. Claezon, V.V. Kakkar, J. Deadman, The facile synthesis of O, O-dialkyl 1-aminoalkane phosphonates, Tetrahedron Lett. 34 (43) (1993) 6917–6920.
[25] F.R. Attherton, C.H. Hassall, R.W. Lambert, Synthesis and structure-activity relationships of antibacterial phosphonopeptides incorporating (1-aminoethyl) phosphonic acid and (aminoalkyl) phosphonic acid, J. Med. Chem. 29 (1) (1986) 29–40.
[26] A.M. Zomova, Z.V. Molodykh, L.A. Kudryavtseva, L.V. Tylepyakova, S.B. Fedorov, B.E. Ivanov, Antimicrobial activity of O, O-diethyl N-alkylaminomethyl-phosphonates and O-ethyl N-alkylaminomethylphosphonates, Pharm. Chem. J. 20 (11) (1986) 774–777.
[27] S. Yang, X.W. Gao, C.L. Diao, B.A. Song, L.H. Jin, G.F. Xu, P. Lu, Synthesis and antifungal activity of novel chiral α-aminophosphonates containing fluorne moi- ety, Chin. J. Chem. 24 (11) (2006) 1581–1588.
[28] H. Kleczynska, J. Sarapuk, New aminophosphonates with antioxidant activity, Cell. Mol. Biol. Lett. 6 (1) (2001) 83–92.
[29] D.G. Ahn, J.K. Choi, D.R. Taylor, J.W. Oh, Biochemical characterization of a recombinant SARS coronavirus nsp12 RNA-dependent RNA polymerase capable of copying viral RNA templates, Arch. Virol. 157 (11) (2012) 2095–2104.
R. kerlour, N. Chafai, O. Moumeni et al.

Journal of Molecular Structure 1272 (2023) 134196